Lockheed Martin (LMT) shares trade at $641.38 after a 27% one-month surge driven by a record backlog and a Morgan Stanley upgrade. The balance of evidence still leans positive for the next two to six weeks, with medium conviction. The weekly and daily trends point up and the stock is leading the market. But an RSI of 85 and a quiet tape keep that reading short of strong.
Why it matters
The rally rests on third-quarter earnings. LMT beat estimates, and its order backlog reached $292 billion, up from $194 billion at the start of the year, with growth concentrated in higher-margin missiles and fire control, including a seven-year PAC-3 contract worth up to $58.6 billion, The Motley Fool reports. The latest headlines add capacity rather than surprise. The company closed its $3.45 billion Ultra Maritime acquisition on November 1. On November 2 it announced a $420 million expansion in Camden, Arkansas to raise PAC-3, THAAD and Precision Strike Missile output.
The market treated all of this as known. The stock slipped 0.28% today and sits 0.3% below its October 29 closing peak of $643.59. The big repricing happened on the earnings and backlog numbers. The new announcements added little.
Over five days LMT rose 2.95% while SPY fell 2.06%, and over a month the stock is up 26.9% against a 2.05% decline for SPY. No sector benchmark is available, so the move cannot be split between sector and stock. The gap to the market is the stock's own. The news explains the direction of that move, namely the upgrade, the backlog and the contracts. It does not explain the size of a 27% month, which also reflects buyers chasing a strong trend.
The debate is lopsided. Morgan Stanley's Kristine Liwag upgraded the stock to overweight on the multi-year F-35 deal and set a Street-high price target, Bloomberg reported. A Nasdaq piece makes the backlog case directly. A Nasdaq analyst roundup is neutral, noting the earnings beat and record backlog. None of the coverage in this set argues against the stock, so the skeptical case comes from the price. The stock is up sharply in a month, its RSI is 85.44, and today's volume is 53.3% below its 20-day average.
Valuation leaves little cushion. Twenty-one analysts rate the stock a consensus buy with a mean price target of $652.57, only 1.7% above the current price. Targets run from $498 to $835. For the stock to move far beyond the average target, estimates and targets have to rise further.
What the evidence says
The long-term thesis is intact. The price is above its 40-week average, well above the 50-day average at $547.24 and the 200-day average at $569.03. It has gained 25.1% over six months and 32.6% year to date, against 10.5% for SPY. Over 50 days it leads the S&P 500 by 19.2%, and over 200 days by 8.4%. The stock is 46% above its 52-week low of $439.19 and 5.2% below the high of $676.70. That makes it a mature advance in an extended stage, not a fresh breakout from a base.
For the next two to six weeks the evidence leans positive, with medium conviction: two of four checks are met. The daily trend runs with the weekly uptrend, and the stock is leading the market. The other two checks are not met, which is why conviction stops at medium. The strongest case against the reading is stretch. A 26.9% gain in a month, an RSI of 85.44, a price within 1.7% of the mean analyst target and volume more than half below average all point to a stock that could consolidate. That does not tip the balance. The trend structure is unbroken and the price sits within 0.3% of its peak, not in a retreat. But it is the reason the reading is not stronger.
Levels that matter
The structure holds above $635.98, a swing zone just under the current price. A move below it would be the first crack. The trend ends below $594.22, another swing zone, and the measure there is a weekly close. The $600 round number sits just above that level, and the 200-day average at $569.03 lies below it. A break of $594.22 would erase most of the October advance.
The breakout level is a daily close above $650 on volume above its 20-day average. Volume is currently well below that mark. From $650 the first target is the 52-week high at $676.70, with the breakout wrong below $630.84, which is $635.98 minus a quarter of the 14-day ATR of $20.57. That gives 1.4 to 1, and the math does not reach 3 to 1. Even the $700 round number beyond the high would not lift it to 3 to 1 against that stop. It would take a tighter stop or a target well past $700.
What would change the picture
A weekly close below $594.22 would change the picture, because it would mean the swing zone behind the whole October advance had failed. The non-price fact that could do it is the F-35 multi-year deal that Morgan Stanley cites as the upgrade's anchor coming apart or being delayed. That would undercut both the backlog story and the Street's rising targets.
What to watch
- Earnings, January 26, 2027: the number that matters is the backlog, now $292 billion. The question is whether it holds up and keeps converting to sales at the higher margins the missiles segment brings.
- Sector events: Gulf states are hoping the U.S. skips further strikes on Iran after the midterm elections, with President Trump saying negotiations are going well. De-escalation would test how much geopolitical premium is in defense shares. Allied spending is the other thread, with Canada committing over half a trillion dollars to defence over the next decade, per GlobeNewswire.
- Valuation: at $641.38 the stock is 1.7% below the $652.57 mean target, within a $498 to $835 range.